Abstract
The emergence of the new Brazilian variant of concern, P.1 lineage (Gamma), raised concern about its impact on the epidemiological profile of COVID-19 cases due to its higher transmissibility rate and immune evasion ability. Using 272 whole-genome sequences combined with epidemiological data, we showed that P.1 introduction in São José do Rio Preto, São Paulo, Brazil, was followed by the displacement of eight circulating SARS-CoV-2 variants and a rapid increase in prevalence two months after its first detection. Our findings support that the P.1 variant is associated with an increase in mortality risk and severity of COVID-19 cases in younger aged groups, which corresponds to the unvaccinated population at the time. Moreover, our data highlight the beneficial effects of vaccination indicated by a pronounced reduction of severe cases and deaths in immunized individuals, reinforcing the need for rapid and massive vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge Rede Corona-Omica BR MCTI/FINEP affiliated to RedeVirus/MCTI (FINEP= 01.20.0029.000462/20, CNPq= 404096/2020-4, CNPq fellowship= 382032/2020-9 to C.A.B), FINEP (Grant #01180149-00), Multiuser Laboratory (LMU) at Sao Jose do Rio Preto School of Medicine (FAMERP), Brazil, for their support with the use of equipments (MiSeqTM, Illumina Inc, USA). Funding support is acknowledged from FAPESP-COVID Program (Grant #2020/04836-0 to MLN), JBS Support for COVID-19 Response Research, FAPESP fellowships (2020/07419-0 to GRFC), Fundacao Butantan (FAPESP Grant #2020/10127), Capes (Grant #0001), and partly by the Centers for Research in Emerging Infectious Diseases (CREID), The Coordinating Research on Emerging Arboviral Threats Encompassing the Neotropics (CREATE-NEO) grant 1U01AI151807 awarded to NV by the National Institutes of Health (NIH/USA). MLN, PR, JPAJ are CNPq Research Fellows. The funders had no role in the design of the study, collection, analyses, or interpretation of data, writing of the manuscript, or in the decision to publish the results.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of Faculdade de Medicina de Sao Jose do Rio Preto Institutional Review Board (protocol number: CAE# 31588920.0.0000.5415)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data availability All SARS-CoV-2 genomes generated and analyzed in this study are available at EpiCoV database in GISAID (https://www.gisaid.org), and their respective access number are available at Supplementary Material.
